Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Biolase but lowers the price target from $3.5 to $2.
September 03, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Biolase but reduces the price target from $3.5 to $2, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in Biolase's potential, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100